{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:58:02Z","timestamp":1786550282456,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/ctg.2018.1","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T11:30:29Z","timestamp":1518694229000},"page":"e133","source":"Crossref","is-referenced-by-count":23,"title":["Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Beh\u00e7et's disease"],"prefix":"10.14309","volume":"9","author":[{"given":"Shulan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Roggenbuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schierack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Reinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210317","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.autrev.2014.01.029","article-title":"Diagnosis and classification of crohns disease.","volume":"13","author":"Laass","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R2-1-20210317","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","article-title":"Diagnosis and classification of ulcerative colitis.","volume":"13","author":"Conrad","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R3-1-20210317","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease.","volume":"361","author":"Abraham","year":"2009","journal-title":"The New England journal of medicine"},{"key":"R5-1-20210317","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ajg.2008.162","article-title":"Differentiating intestinal tuberculosis from crohns disease: A diagnostic challenge.","volume":"104","author":"Almadi","year":"2009","journal-title":"The American journal of gastroenterology"},{"key":"R6-1-20210317","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12969-017-0162-4","article-title":"Intestinal behcet and crohns disease: Two sides of the same coin.","volume":"15","author":"Valenti","year":"2017","journal-title":"Pediatric rheumatology online journal"},{"key":"R7-1-20210317","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/jcp.2003.015214","article-title":"Indeterminate colitis.","volume":"57","author":"Guindi","year":"2004","journal-title":"J Clin Pathol"},{"key":"R8-1-20210317","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/bjs.1800780214","article-title":"Natural history of indeterminate colitis.","volume":"78","author":"Wells","year":"1991","journal-title":"Br J Surg"},{"key":"R9-1-20210317","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1053\/j.gastro.2010.11.058","article-title":"The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.","volume":"140","author":"Lewis","year":"2011","journal-title":"Gastroenterology"},{"key":"R10-1-20210317","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.3748\/wjg.v19.i37.6207","article-title":"Inflammatory bowel disease serology in asia and the west.","volume":"19","author":"Prideaux","year":"2013","journal-title":"World journal of gastroenterology"},{"key":"R11-1-20210317","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1572-0241.2004.40486.x","article-title":"A prospective comparative study of asca and panca in chinese and caucasian ibd patients.","volume":"99","author":"Lawrance","year":"2004","journal-title":"The American journal of gastroenterology"},{"key":"R12-1-20210317","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1515\/cclm-2016-0658","article-title":"Retrospective evaluation of the clinical utility of serological biomarkers in chinese patients with inflammatory bowel disease: 2-year clinical experience.","volume":"55","author":"Zhang","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"R13-1-20210317","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10620-006-9527-0","article-title":"Anti-saccharomyces cerevisiae antibody does not differentiate between crohns disease and intestinal tuberculosis.","volume":"52","author":"Makharia","year":"2007","journal-title":"Digestive diseases and sciences"},{"key":"R15-1-20210317","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1136\/gut.2008.162495","article-title":"Identification of gp2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in crohns disease.","volume":"58","author":"Roggenbuck","year":"2009","journal-title":"Gut"},{"key":"R16-1-20210317","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.crohns.2012.12.013","article-title":"Loss of tolerance to one or two major targets in crohns disease or just cross-reactivity?","volume":"7","author":"Roggenbuck","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R17-1-20210317","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.crohns.2012.10.011","article-title":"Autoantibodies against exocrine pancreas in crohns disease are directed against two antigens: The glycoproteins cuzd1 and gp2.","volume":"7","author":"Komorowski","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R18-1-20210317","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/bs.acc.2016.06.002","article-title":"Autoimmunity in crohns disease-a putative stratification factor of the clinical phenotype.","volume":"77","author":"Roggenbuck","year":"2016","journal-title":"Adv Clin Chem"},{"key":"R19-1-20210317","doi-asserted-by":"crossref","first-page":"640835","DOI":"10.1155\/2012\/640835","article-title":"Ileal inflammation may trigger the development of gp2-specific pancreatic autoantibodies in patients with crohns disease.","volume":"2012","author":"Pavlidis","year":"2012","journal-title":"Clinical developmental immunology"},{"key":"R20-1-20210317","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-230X-12-102","article-title":"Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with crohns disease.","volume":"12","author":"Bogdanos","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"R21-1-20210317","doi-asserted-by":"crossref","first-page":"e1654","DOI":"10.1097\/MD.0000000000001654","article-title":"Diagnostic potential of zymogen granule glycoprotein 2 antibodies as serologic biomarkers in chinese patients with crohn disease.","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R24-1-20210317","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a crohns disease activity index. National cooperative crohns disease study.","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"R25-1-20210317","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cca.2017.05.018","article-title":"Peripheral differentials by cytodiff flow cytometric system predict disease activity in chinese patients with inflammatory bowel disease.","volume":"471","author":"Zhang","year":"2017","journal-title":"Clin Chim Acta"},{"key":"R27-1-20210317","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach.","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"R28-1-20210317","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1097\/MIB.0000000000000936","article-title":"Serologic anti-gp2 antibodies are associated with genetic polymorphisms, fibrostenosis, and need for surgical resection in crohns disease.","volume":"22","author":"Degenhardt","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R29-1-20210317","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gutjnl-2016-311739","article-title":"Anti-gp2 iga autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.","volume":"66","author":"Jendrek","year":"2017","journal-title":"Gut"},{"key":"R32-1-20210317","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.cca.2011.02.005","article-title":"Antibodies to glycoprotein 2 (gp2) in patients with inflammatory bowel diseases from uk.","volume":"412","author":"Pavlidis","year":"2011","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"key":"R34-1-20210317","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/ibd.21903","article-title":"Serological antibodies in inflammatory bowel disease: A systematic review.","volume":"18","author":"Prideaux","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R35-1-20210317","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mi.2013.30","article-title":"Microfold (m) cells: Important immunosurveillance posts in the intestinal epithelium.","volume":"6","author":"Mabbott","year":"2013","journal-title":"Mucosal immunology"},{"key":"R36-1-20210317","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/gutjnl-2014-307854","article-title":"Species-specific and pathotype-specific binding of bacteria to zymogen granule membrane glycoprotein 2 (gp2).","volume":"64","author":"Schierack","year":"2015","journal-title":"Gut"},{"key":"R37-1-20210317","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature08529","article-title":"Uptake through glycoprotein 2 of fimh() bacteria by m cells initiates mucosal immune response.","volume":"462","author":"Hase","year":"2009","journal-title":"Nature"},{"key":"R38-1-20210317","doi-asserted-by":"crossref","first-page":"683824","DOI":"10.1155\/2013\/683824","article-title":"The novel crohns disease marker anti-gp2 antibody is associated with ileocolonic location of disease.","volume":"2013","author":"Somma","year":"2013","journal-title":"Gastroenterology research and practice"},{"key":"R39-1-20210317","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1097\/MIB.0000000000000564","article-title":"Pancreatic autoantibodies against cuzd1 and gp2 are associated with distinct clinical phenotypes of crohns disease.","volume":"21","author":"Michaels","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R40-1-20210317","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1515\/cclm-2015-0376","article-title":"Diagnostic and clinical significance of crohns disease-specific pancreatic anti-gp2 and anti-cuzd1 antibodies.","volume":"54","author":"Pavlidis","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"R41-1-20210317","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/ecco-jcc\/jjv087","article-title":"Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of crohns patients: The importance of specific target antigens gp2 and cuzd1.","volume":"9","author":"Papp","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R42-1-20210317","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.4049\/jimmunol.1103190","article-title":"Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses.","volume":"189","author":"Werner","year":"2012","journal-title":"Journal of immunology"},{"key":"R43-1-20210317","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-12-407681-5.00006-4","article-title":"Glycoprotein 2 antibodies in crohns disease.","volume":"60","author":"Roggenbuck","year":"2013","journal-title":"Adv Clin Chem"}],"container-title":["Clinical and Translational Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01720094-201802000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:21:37Z","timestamp":1786548097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01720094-201802000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1038\/ctg.2018.1","relation":{},"ISSN":["2155-384X"],"issn-type":[{"value":"2155-384X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}